Purpose: Inadequate relief of pain is common in prehospital and hospital emergency department (ED) settings. We investigated pain treatments and timelines in patients receiving pre-hospital and hospital ED care to provide insight into potential approaches to reduce the burden of trauma-related pain. Patients and methods: In this observational, retrospective chart review, patients had received emergency care for musculoskeletal trauma injuries and analgesic treatment for moderate-to-severe pain in Belgium, France, Germany, Italy, Spain or Sweden. As inhaled low-dose methoxyflurane (LDM) is used extensively in Australia but was not widely available in Europe at the time of this analysis, data from Australia were collated to provide insight into the potential utility of this analgesic in Europe. The primary endpoint was time to administration of first pain relief treatment following arrival of paramedic/ED care. Results: Randomly selected physicians (n=189) collated data from 856 patients (Europe: n=585; Australia: n=271) via an online survey. Time to first pain relief treatment varied between countries and was significantly longer across Europe versus Australia (mean [SD] 38.1 [34.7] vs 29.9 [35.5] mins; P=0.0017). Patients from Australia who received LDM experience a shorter mean (SD) time to first pain treatment following arrival of emergency care versus patients who received other analgesics (propensity score matched [n=85] per group: 21.7 [24.2] vs 39.1 [43.0] mins; P=0.0013). Across all countries, mean (SD) time to first analgesic was shorter when treatment was administered by paramedics versus hospital ED staff (15.7 [14.7] vs 49.1 [38.4] mins).
Introduction
Effective pain management is a key component of care for the estimated 38 million injured people treated in European hospital emergency departments (ED) every year. 1 Undertreated pain not only poses an immediate burden to patients, but may also result in psychological consequences, physiological effects which delay healing, and lead to increased healthcare resource utilization. 2, 3 However, inadequate relief of traumarelated pain is common despite recommendations that patients with moderate-to-severe pain receive analgesia with 15-20 mins of arriving at hospital EDs. 4, 5 Studies suggest the majority of patients attending European EDs with moderate-tosevere pain receive no analgesia, and high levels of pain are frequently reported by patients when discharged from EDs. [6] [7] [8] [9] Furthermore, suboptimal management of moderate-to-severe trauma pain is also common in pre-hospital emergency care settings. 10, 11 Patients may face numerous barriers to effective control of trauma-related pain, including inadequate assessment of their pain and prolonged waiting times in hospital EDs. 12 Analgesics commonly used for moderate-to-severe pain in emergency settings including N 2 O, ketamine and opioids are also associated with limitations. 12 For example, while opioids can provide effective analgesia for selected patients with severe pain, some health care professionals (HCPs) are reluctant to administer these analgesics due to concerns regarding patient drug-seeking behavior or addiction, increased demands for patient monitoring and fear of masking other symptoms of trauma. 12, 13 Delays to analgesia may also result from difficulties obtaining intravenous (IV) access in some emergency settings. Also, the bulky equipment (cylinders and breathing apparatus) required for N 2 O treatment can limit its practicality in some prehospital settings. 12 Inhaled, low-dose methoxyflurane (LDM) is a nonopioid analgesic. The efficacy and safety of LDM as an analgesic for trauma-associated pain and for medical procedures have recently been reviewed. 14 Patients can self-administer this volatile fluorinated hydrocarbon under medical supervision via the handheld, Penthrox ® "green whistle" inhaler. LDM provides rapid pain relief, occurring within 6-10 inhalations, which is maintained for 25-30 mins (intermittent inhalation may provide longer relief). 15 LDM has been licensed in Australia for over 30 years where it has been widely used to provide short-term relief of acute pain in adults and children in hospital EDs and prehospital emergency care settings. 16, 17 In Europe, LDM was approved in 2015 for emergency relief of moderate-to-severe trauma-associated pain in conscious adults, based on evidence from the Phase III STOP! study (NCT01420159). This study demonstrated significantly greater reductions in pain scores with LDM compared with placebo and a rapid onset of pain relief (median of 4 mins) in adult and adolescent patients attending UK hospital EDs due to trauma injuries. 18 Due to its non-opioid mechanism of action, rapid onset of action and portability, LDM has the potential to overcome several barriers associated with the use of some more established analgesic agents in Europe. The aim of this retrospective, real-world study was to obtain greater insight into pain treatments and timelines to pain relief experienced by patients with trauma-related injuries in Europe. Given that LDM was not yet marketed in Europe at the time of this analysis, data from Australia, where LDM is used extensive, were also analyzed to provide insight into the potential impact of this treatment on analgesic on time to administration of first pain relief following arrival of paramedic/ED care.
Methods

Study design
This retrospective chart review was conducted to examine timelines and treatment outcomes in medical emergency situations where pain relief was administered to patients in 6 European countries (Belgium, France, Germany, Italy, Spain and Sweden) and Australia. Data were collected via an online survey which was completed by a random sample of physicians working in the ED who were recruited using nationally representative managed databases. Physicians included in this survey had practiced medicine for >3 years, worked at their ED during the prior 6 months and had personally managed or treated >3 adult patients per week in emergency settings.
Each physician was asked to identify four eligible patients (≥18 years of age) who they had treated most recently within the prior 6 months. Eligible patients had sustained acute musculoskeletal trauma injuries (compression, dislocation, laceration, sprain/strain, contusions, other type of injury of the lower limbs, upper limbs, head, abdominal, chest/thorax, spine, or other site) which required paramedic or other form of emergency care. All patients had moderate-to-severe pain, which had been assessed using a numerical rating scale (NRS; ≥4 [0-10 scale]) or visual analog scale (VAS; ≥40 [0-100 scale]) and received analgesic treatment. Patients must have remained conscious throughout the emergency event and were excluded if an altered level of consciousness had occurred due to any cause, including head injury, drugs, or alcohol. Patients were also excluded who self-reported clinically significant renal impairment or had clinical evidence of respiratory depression or cardiovascular instability at the time of the emergency event.
Study objectives and data collection
The primary objective was to determine the time to administration of the first analgesic following arrival of paramedic or ED HCP assistance. In the patients from Australia, time to pain relief was also compared between individuals receiving LDM versus those receiving other analgesics as their first pain relief treatment (non-LDM). Secondary objectives included assessment of the patients' demographic and clinical characteristics, including the pain experienced; investigating the association between time to analgesic treatment and time to discharge from hospital; and obtaining insight into emergency pain treatment, including the first and subsequent pain medications administered, type of HCP administering analgesia and hospitalization details.
Physicians reviewed the patients' medical charts and reported anonymized patient-level information using an online data abstraction form. Data collected included: characteristics of the patient, trauma/injury and associated pain; time from emergency call to the arrival of a paramedic or emergency HCP; time from arrival of a paramedic or emergency HCP to administration of first pain relief treatment and pain relief treatments received. The following time durations were also recorded: arrival of paramedic to arrival at hospital ED; arrival at hospital ED to ED admission and ED admission to hospital discharge. Time to surgery during hospitalization, time to admission to intensive care unit (ICU) and duration of ICU stay were also recorded (data not reported). The physicians also rated the severity of the injury based on their clinical judgment (mild, moderate or severe). Pain severity was based on NRS or VAS pain scale data recorded in the patient charts. In Australia, where LDM is used in routine practice, physicians were asked to identify patients treated with LDM or other pain relief medications.
Statistical methods
Data obtained from all physicians and patients meeting the inclusion criteria were included in the analyses. The primary endpoint (time to first analgesic administration following arrival of paramedic or ED HCP) and other time interval endpoints were compared between the European and Australian datasets using 2-sided Student's t-tests. T-tests were also used to compare time interval endpoints in the LDM and non-LDM Australian subgroups. Due to the rightskewed nature of the primary endpoint data, a non-parametric treatment group comparison was performed using Wilcoxon Rank-Sum test for sensitivity. Patient demographic and clinical characteristics of the Australian LDM and non-LDM groups were compared using t-tests and Chisquare tests, as appropriate. Due to the non-randomized design of this study, propensity score matching (PSM) was used to adjust for confounding between LDM and non-LDM Australian subgroups. The propensity scores for LDM treatment were evaluated using a logistic model with baseline covariates for age, gender, geographic location, race, injury type, injury severity and pain severity, and patients were matched using a nearest neighbor caliper algorithm set at 0.25 standard deviations (SD). No statistical comparisons were conducted between the European countries.
All statistical tests were two-sided and used a 5% significance level. As the primary analysis was descriptive in nature, a power calculation for comparative analysis was not applicable. A sample of 100 patients per country was expected to provide good precision for the primary endpoint. For the comparisons between LDM and non-LDM Australian subgroups, 100 patients per treatment group provided a maximum of 80% power to detect a small-to-medium Cohen's d effect size of 0.40 with a significance level of 5%.
Ethical issues
This research survey was conducted in compliance with the protocol and the Code of Conduct of the European Pharmaceutical Market Research Association (EphMRA) and the Australian Market and Social Research Society (AMSRS). All data were collected by physicians, no patient-identifying data (e.g., initials, date of birth or ZIP code) were obtained and patient anonymity was strictly guaranteed. Also, no tabulation/record form linking the patient number and name was used.
Results
Physician characteristics
Between December 2016 and February 2017, the online survey was completed by 189 eligible physicians from 145 hospitals, of whom n=48 and n=141 were recruited in Australia and Europe (Belgium n=19, France n=28, Germany n=27, Italy n=27, Spain n=25, Sweden n=15), respectively.
Most physicians were ED specialists (57%) or specialized in internal medicine (18%) or general medicine (15%). The mean (SD) time physicians had been practicing in their medical specialty was similar in Europe (14. 
Patient characteristics
Medical charts of 856 eligible patients were reviewed, including 585 from Europe (48 to 113 charts per country) and 271 from Australia. Of the Australian patients, n=128 were treated with LDM as their first analgesic (LDM group) and n=118 received no LDM (non-LDM group). Data from n=25 Australian patients were not allocated to LDM/non-LDM groups as their first pain treatment was administered prior to paramedic or emergency staff arrival or they received LDM as a second or later analgesic. Across all countries, patients' mean (SD) age was 46.7 (20.2) years and ranged from 18 to 104 years ( 
Injury and pain characteristics
Broadly similar injury types were reported in Europe and Australia, with fractures being the most common injury type (38% and 35%, respectively [ Table 2 ]). Fractures were most frequently reported in Belgium (50%) and less common in the German cohort (21%) where compressions were the most common injury (28%). Sprains/strains were reported in 20% of the patients from both Europe and Australia while there was a higher proportion of dislocations (8% vs 17%) and lacerations (7% vs 17%) and fewer contusions (22% vs 10%) and compressions (10% vs 2%) occurring in the latter ( Table 2 ). While injury severity varied between individual countries, across Europe (64%) and Australia (62%) most injuries were rated as "moderate" ( Table 2 ). NRS (n=678) was used more frequently that VAS (n=178) to assess patient-reported pain ( Table 2) . Moderate pain was the most common pain severity category reported across all countries (73% of the cases) with severe pain being reported in the remaining 27% of the cases.
There were some differences in injury type and pain characteristics between the unmatched LDM and non-LDM subgroups of Australian patients, including frequencies of fractures (43% vs 27%, P=0.0094), contusions (5% vs 13%, P=0.0467) and compression injuries (0 vs 4%, P=0.0186). Also, while moderate injury severity was more frequent in the LDM versus non-LDM subgroup (72% vs 51%, P=0.0022), most patients reported moderate pain in both groups (74% vs 72%, P>0.05). In the PSM LDM and non-LDM groups (both, n=85) injury and pain characteristics were similar (P>0.05 all comparisons), with fractures (35% vs 35%) and sprain/strain (19% vs 21%) being the most frequent injury types. Injury severity was most commonly rated as moderate (58% vs 58%), and most patients reporting moderate pain severity (74% vs 74%) in the PSM, LDM and non-LDM groups.
Pain relief treatment timelines
The mean (SD) time from emergency call to arrival of the paramedic was 24.4 (18.9) mins across all countries, ranging from 13.1 mins in Belgium and Germany to 34.1 mins in Spain ( Table 3 ). The mean (SD) time from 35 (13) 17 (13) 15 (13) 41 (6) Aboriginal Australian 3 (1) 1 (1) 1 (1) 12 (1) Notes: a LDM/Non-LDM groups are based on the Australian sample. Twenty-five Australian patients were not allocated to LDM/non-LDM groups as their first pain treatment was administered prior to paramedic or emergency staff arrival or they received LDM as a second or later analgesic. b
All patients from Europe and Australia.
Abbreviations: LDM, low-dose methoxyfluoride; NR, not reported; SD, standard deviation. 3 (6) 49 (8) 45 (17) 23 (18) 15 (13) 94 (11) Laceration 10 (9) 3 (3) 10 (9) 11 (10) 3 (3) 4 (8) 41 (7) 46 (17) 19 (15) 22 (19) 87 (10) Fracture (18) 12 (25) 117 (20) 53 (20) 26 (20) 22 (19) 170 (20) Contusion 21 (19) 25 (23) 27 (25) 28 (26) 22 (22) 3 (6) 126 (22) 26 (10) 7 (5) 15 (13) 152 (18) Other 15 (13) 13 (12) 2 (2) 6 (6) 10 (10) 4 (8) 50 (9) 14 (5) 3 (2) 10 (9) 64 (8)
Injury severity d , n (%)
Mild 22 (20) 21 (20) 1 (1) 21 (19) 20 (20) 15 (31) 100 (17) 66 (24) 21 ( 18 (17) 20 (19) 15 (14) 17 (17) 5 (10) 112 (19) 37 (14) 15 (12) 19 (16) 149 ( 
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Open Access Emergency Medicine 2019:11 Table 3 Pain relief timelines (full analysis set) First analgesic was administered after arrival of emergency care by a paramedic or hospital ED staff member in most cases (n=831 [97%]). Across all countries, for these patients, the mean (SD) time to first analgesic was shorter when the treatment was administered by paramedics versus hospital ED staff (15.7 [14.7] Table 3 ]). In 5 of the 6 European countries combined, the first analgesic was provided by a paramedic in only 24% of the patients on average and was rarely administered in the ambulance, prior to arrival at the hospital ED (10%). Sweden was the only European country in which the first analgesic was administered by paramedics (60%) and provided in an ambulance (54%) for most patients, as was also observed in Australia (70% and 62%, respectively). Subgroup analysis of the Australian cohort revealed a high proportion of patients received LDM during paramedic care (88%) and while in an ambulance (80%) compared with patients who received other analgesics (non-LDM: 49% and 45%, respectively). Also, the mean (SD) time to first pain relief treatment after arrival of emergency care (primary endpoint) was significantly lower in the LDM versus non-LDM group (PSM subgroups: mean [SD] 21.7 [24.2] vs 39.1 [43.0] mins, P=0.0013: Figure 1) . Similar findings were observed in the full analysis set (19.9 [22.1] vs 42.0 [43.9] mins, P<0.0001) and in the non-parametric sensitivity analysis (median 11.0 vs 25.5 mins, P<0.0001).
There was no evidence for a relationship between time to pain treatment and time to discharge from hospital (correlations in all countries were <0.3). Unadjusted (P=0.70) and adjusted (P=0.86) linear regression models incorporating data from all countries also indicated no evidence of a relationship between time to pain treatment and time to hospital discharge. Pain relief treatments A wide range of analgesics were administered as first pain relief treatment across Europe, with IV paracetamol (n=129, 22%), IV NSAID (n=114, 19%), oral paracetamol (n=98, 17%) and IV opioid (n=77, 13%) being most frequently used in this setting ( Figure 2 ). While LDM was rarely used in Europe (n=12, 2%), it was the most frequent analgesic first administered to patients in Australia (n=129, 48%). IVopioid (n=38, 14%) and oral paracetamol (n=25, 9%) were the second-and third-most frequently administered first analgesics to patients in Australia, respectively ( Figure 2) . Overall, 43% of the patients received subsequent pain treatment. The most frequently used subsequent pain medications in Europe were IV opioids (n=63, 11%), IV NSAIDs (n=55, 9%) and IV paracetamol (n=51, 9%). In Australia, there were 11 (4.1%) instances where LDM was given as the subsequent analgesic medication, while strong oral opioid (n=50, 18%), IV opioids (n=26, 10%) and oral NSAIDs (n=25, 9%) were administered most frequently (Figure 3 ).
Discussion
While effective pain management is an important part of emergency care, oligoanalgesia is frequently reported and can have a substantial impact on patients' physical and emotional wellbeing. 2, 6, 11 Understanding pain treatments, timelines and outcomes in emergency care may provide insight into potential approaches to reduce the burden of trauma-related pain. To our knowledge, this is the first study to investigate the time to pain relief treatment experienced by patients with acute musculoskeletal injuries and moderate-to-severe pain who received emergency care by paramedics and/or hospital ED HCPs across 6 European countries and Australia. While LDM was approved in Europe for conscious adults with traumarelated pain in 2015, it was not widely available at the time of this analysis. Consequently, data from patients treated in emergency settings in Australia, where LDM is used extensive, were included in this analysis.
This analysis of real-world data from medical charts of 856 patients revealed substantial variation in the time to administration of first pain relief treatment following arrival of paramedic or ED HCP in Europe (mean [SD] 19.5 [8.3] . While this may be unsurprising, given that paramedics are often the first HCP to attend injured patients, it is noteworthy that in 5 of the 6 European countries combined, the first analgesic treatment was rarely provided by paramedics (24%) or administered in an ambulance (10%). This observation suggests that increased utilization of analgesics by paramedics may enable more patients with acute, musculoskeletal injuries to receive analgesia promptly. Some of the variation in time to first analgesia may be attributed to regulatory barriers which prevent ambulance personnel from administering opioid analgesics in some countries. 13 Furthermore, some paramedics and patients may express a preference for non-IV pain relief treatments. Consequently, it is feasible that greater utilization of non-opioid, needle-free analgesics by paramedics which can provide effective relief of moderateto-severe pain may result in a faster time to first pain relief treatment. This was evidenced by the use of LDM in Australia in the present study and is supported by a recent systematic review which concluded that while both LDM and N 2 O provide rapid analgesia in trauma settings, ease of administration and portability of LDM may be of significant value across a range of emergency care settings. 19 Absence of a relationship between time to pain relief treatment and time to discharge from hospital demonstrated in this study is perhaps unsurprising, given there are many clinical considerations which influence time to hospital discharge that are unrelated to the timing of first pain treatment. These may include hospital occupancy, availability of medical staff, other treatment required for the underlying injuries, as well as variations in hospital protocols regarding monitoring time following strong pain relief treatments. Given the geographic coverage provided by the 856 patient charts across seven countries from a large number of hospitals (n=145) and physicians (n=189), this study likely provides a robust picture of analgesic timelines for patients with acute musculoskeletal injuries in real-world practice compared with clinical studies that would typically involve a limited number of centers. Single-center observational studies reporting waiting times in excess of 40 mins in European hospital ED for patients with moderate-to-severe pain support these findings. 9, 20 Nevertheless, this retrospective study was associated with some limitations. In order to study time to pain relief in a relatively homogenous population, this analysis focused on adults with moderate-to-severe pain associated with acute musculoskeletal injuries. While it is anticipated that these findings may be relevant for patients with moderate-to-severe resulting from other injuries or conditions, additional research in a broader emergency trauma population is warranted. Furthermore, while these data indicate that utilization of LDM in Europe may facilitate the timely relief of moderate-to-severe pain in emergency care to lessen patient suffering, further studies are needed to monitor the impact of LDM as a pain relief treatment option in Europe following its relatively recent approval.
In summary, this real-world observational study indicated an unmet need for timely administration of pain relief in patients with moderate-to-severe pain following musculoskeletal injury in Europe. Data from comparable patients receiving emergency care in Australia indicate that utilization of inhaled analgesics such as LDM by European paramedics could result in more timely pain relief for appropriately selected patients.
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